Key points from article :
Isomorphic Labs, an AI-driven drug discovery company founded within Google parent Alphabet, has raised $600 million in its first external funding round. The funding, led by Thrive Capital with participation from GV and Alphabet, will accelerate development of the company’s next-generation AI model for designing new drugs and support the advancement of its internal drug programs into clinical trials.
At the core of Isomorphic’s technology is AlphaFold 3, a powerful AI model developed in collaboration with Google DeepMind. This model can predict the 3D structures and interactions of molecules with high accuracy—a major breakthrough in computational biology. Isomorphic’s CEO and co-founder, Demis Hassabis, Ph.D., and his DeepMind colleague John Jumper, Ph.D., were jointly awarded the 2024 Nobel Prize in Chemistry for their pioneering work on AlphaFold.
The company has already struck major deals with pharmaceutical giants Eli Lilly and Novartis, valued at nearly $3 billion in total, to use its AI tools to identify small-molecule drug candidates for undisclosed targets. While these partnerships are a key part of its strategy, Isomorphic is also developing its own in-house drug programs.
With this new funding and a foundation of Nobel Prize-winning science, Isomorphic is emerging as a leader in the rapidly growing field of AI-powered biotech, aiming to use artificial intelligence to tackle some of medicine’s most complex challenges.
